Intricon Corp (Nasdaq:IIN) announced it has received 510(k) marketing clearance from the U.S. Food and Drug Administration (FDA), for the Centauri Ambulatory Patient ECG, its first-generation wireless cardiac diagnostic monitoring (CDM) device. The Centauri combines event recording with wireless transmission of patient data allowing physicians to continuously monitor patient cardiac events remotely.
Read full article:http://bestotc.com/17816/stock-alerts/iin-crwe-blin-zstn-stocks-in-focus-by-bestotccom/
(IIN, CRWE, BLIN, ZSTN) Stocks in Focus by BestOtc.com
August 19th, 2011 at 09:50 am